425: Alumis to Acquire ACELYRIN in Merger Deal, Creating Late-Stage Clinical Biopharma Powerhouse

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement to create a leading clinical biopharmaceutical company focused on immune-mediated diseases.

Summary

• Alumis Inc. and ACELYRIN, Inc. have entered into a merger agreement where Alumis will acquire ACELYRIN.
• The combined company will focus on developing and commercializing therapies for immune-mediated diseases.
• The merger aims to create a late-stage clinical biopharma company with a differentiated pipeline.
• Key assets include ESK-001 (TYK2 inhibitor) for psoriasis and SLE, A-005 (TYK2 inhibitor) for MS, and lonigutamab (anti-IGF-1R) for thyroid eye disease (TED).
• Topline data from the Phase 3 ONWARD trials for ESK-001 in psoriasis is now expected in 1Q 2026.
• Topline data from the Phase 2b LUMUS trial in SLE is expected in 2026.
• A Phase 2 clinical trial for A-005 in MS is planned to be initiated in 2025, with topline data expected in 2026.
• The combined company will have pro forma cash of approximately $737 million as of December 31, 2024, providing runway into 2027.
• ACELYRIN stockholders are expected to own 45% of the combined company.
• The merger is expected to be 41%-48% value accretive to ACELYRIN stockholders.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting potential value creation and a strong pipeline, but also acknowledges risks and uncertainties inherent in such transactions.

Positives

• The merger creates a late-stage clinical biopharma company with a diversified pipeline.
• The combined company has a strong cash position of approximately $737 million, providing a runway into 2027.
• The transaction is expected to be value accretive to ACELYRIN stockholders by 41%-48%.
• The combined company has a world-class leadership team with a proven record of operating discipline and capital efficiency.
• The merger allows for the continued development of lonigutamab for thyroid eye disease (TED) with committed capital of $25-50M.
• ACELYRIN stockholders will have the opportunity to participate in significant upside with 45% ownership in the combined company.

Negatives

• The merger is subject to various closing conditions, including stockholder approvals.
• The announcement, pendency, or completion of the merger could affect the ability to attract, motivate, retain, and hire key personnel.
• The merger may divert management's attention from ongoing business operations.
• There is a risk that the anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• The integration of ACELYRIN's operations and personnel may not occur as anticipated.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The merger could negatively impact the ability to retain key personnel and maintain relationships with partners and suppliers.
• Management's attention may be diverted from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• Economic, business, and competitive factors could adversely affect Alumis or ACELYRIN.
• The anticipated benefits and synergies of the merger may not be fully realized.
• Legislative, regulatory, economic, competitive, and technological changes could impact the combined company.
• The value of Alumis securities to be issued in the proposed transaction is subject to risk.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• Delays in initiating, enrolling, or completing preclinical studies and clinical trials are possible.

Future Outlook

The combined company anticipates multiple near-term milestones, including topline data readouts for ESK-001 in psoriasis and SLE, and initiation of a Phase 2 trial for A-005 in MS. The company expects its cash runway to extend into 2027.

Management Comments

• The ACELYRIN Board determined that a transaction that supported the continued development of lonigutamab represented the best opportunity for long-term value creation for ACELYRIN stockholders.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to create larger entities with diversified pipelines and greater financial resources. This allows companies to spread risk, achieve economies of scale, and pursue a broader range of therapeutic opportunities in the competitive landscape of immune-mediated diseases.

Comparison to Industry Standards

• The document references Tepezza, a treatment for thyroid eye disease, suggesting that Alumis' Chief Commercial Officer has experience in a similar market.
• The document mentions GlobalData market research reports, indicating that the companies are using industry-standard market analysis to assess the potential of their product candidates.
• The document references Guggenheim Securities' discounted cash flow analysis, a common practice in evaluating merger transactions.

Stakeholder Impact

• Shareholders of ACELYRIN are expected to benefit from the value accretion and participation in the combined company's upside.
• Employees of both companies may experience changes as a result of the integration.
• Patients may benefit from the development of new therapies for immune-mediated diseases.

Next Steps

• Alumis intends to file a registration statement with the SEC, including a joint proxy statement/prospectus.
• Stockholder approvals from both Alumis and ACELYRIN will be required.
• The companies will work to satisfy the other conditions to the consummation of the transaction.
• Post transaction close, the combined company expects to evaluate lonigutamab's potential in TED with approximately $25-50M of committed capital.

Key Dates